Thomas F. Gajewski
16Patents
6h-index
22Co-inventors
66Inventor score
Filing activity: Jun 17, 1994 → Sep 18, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9855302B2 | Treatment of cancer by manipulation of commensal microflora | Emerging Cross-Sectional Technologies | 44 | Active |
| US5591430A | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof | Emerging Cross-Sectional Technologies | 18 | Expired |
| US6716422B1 | Vaccine adjuvants for immunotherapy of melanoma | Emerging Cross-Sectional Technologies | 14 | Expired |
| US7381401B2 | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase | Chemistry; Metallurgy | 10 | Expired |
| US6080399A | Vaccine adjuvants for immunotherapy of melanoma | Emerging Cross-Sectional Technologies | 9 | Expired |
| US5851523A | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof | Human Necessities | 8 | Expired |
| US10034939B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | Human Necessities | 3 | Active |
| US9944992B2 | Methods and compositions related to T-cell activity | Emerging Cross-Sectional Technologies | 3 | Active |
| US6682731B1 | Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules | Human Necessities | 2 | Expired |
| US10753938B2 | Beta-catenin inhibitors in cancer immunotherapy | Physics | 1 | Active |
| US10815531B2 | Methods and compositions related to T-cell activity | Emerging Cross-Sectional Technologies | 1 | Active |
| US11566077B2 | Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment | Chemistry; Metallurgy | 0 | Active |
| US11802316B2 | Methods and compositions related to T-cell activity | Chemistry; Metallurgy | 0 | Active |
| US11946936B2 | Beta-catenin inhibitors in cancer immunotherapy | Physics | 0 | Active |
| US11638728B2 | Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof | Human Necessities | 0 | Active |
| US10967060B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.